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Abstract
Background: Triggered by the successive implementation of organized mammography screening programs (MSPs)
throughout western European countries over the last decades, there is an ongoing debate questioning their
effectiveness. Since it is difficult to assess the effect of MSPs on a population level, we rather aim to assess the
impact of the implementation itself on breast cancer mortality rates utilizing an ecological study design.
Methods: We analyzed age group-specific (50–59, 60–69 and 70–79 years) female breast cancer mortality rates in
14 western European countries between 1980 and 2017 using Joinpoint regression, interrupted time series (ITS)
regression and multivariable Poisson regression.
Results: The Joinpoint analysis demonstrated decreasing trends resulting in annual percentage changes ranging
from − 1.5% to − 5.4% (50–59), − 0.2% to − 8.1% (60–69) and 0% to − 7.1% (70–79) depending on the country
within 3 years after MSP implementation. The ITS analysis results in highly significant interaction terms (calendar
year * binary MSP indicator) for all age groups. The multivariable regression using “calendar year”, “year of MSP
implementation” and “years with MSP” as independent variables yielded a significant yearly decrease for “years with
MSP” ranging from 0.9 to 1.2%.
Conclusions: The results of this study suggest a positive association between the implementation of MSPs and the
(accelerated) reduction of breast cancer mortality rates. Measuring and quantifying the isolated effect of MSPs on a
population level will require additional studies using individual data.
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Background
In most western European countries, breast cancer is
the leading malignant neoplasm among women [1]. Its
disease burden has been recognized as a major public
health issue across many countries.
In the early 1980s, a controlled trial was conducted in
two counties of Sweden to examine the effect of an orga-
nized breast cancer screening program which resulted in
an estimated reduction of 30% in long-term breast can-
cer mortality [2]. Since then, additional randomized
controlled trials assessing the effectiveness and other im-
portant aspects around mammography screening pro-
grams (MSPs) were performed in other Swedish
counties as well as European countries [3–6]. Promising
study results and the decision of the “Committee of
Cancer Experts of the European Community” in 1986
led to a roll-out of organized MSPs in many European
countries [7, 8]. These MSPs have been executing their
planning, implementation, and quality assurance accord-
ing to the “European guidelines for quality assurance in
breast cancer screening and diagnosis”, which were intro-
duced in 1993 from the “European reference organization
for quality assured breast screening and diagnostic ser-
vices” (EUREF) and are now available in its 4th version
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from 2006 [9]. These guidelines include a quality-controlled
x-ray based diagnostic approach of a biennial screening
program offered to women in the age range between 50
and 69 years, by trained professionals who should work to-
gether in certified breast centers during the entire process
of invitation, diagnostics, therapy and follow-up of partici-
pants. The EUREF defined about 40 performance indicators
with acceptable and desirable levels, which are supposed to
be monitored continuously. However, none of the Euro-
pean MSPs achieved these recommendations for all per-
formance indicators at an acceptable level [7]. Especially
the acceptable participation of at least 70% is not reached
by all countries (see Table 1).
MSPs are not the only preventive measure conducted to
reduce breast cancer mortality. The so-called “grey” or op-
portunistic screening is a non-organized mammography
screening performed by any specialist upon recommenda-
tion to or request of the patient. In most of the countries
considered in this study, the opportunistic screening could
be observed before the implementation and in coexistence
with systematic screening. The significant difference to
organized programs is the lack of a systematic invitation
process, the absence of quality management instances and
the fact that mammograms may be taken and evaluated in
clinics which are not certified breast centers [19]. Most
importantly there is no central documentation of the exe-
cution and the evaluation of the measure.
Across Europe, a debate emerged on the effectiveness of
MSPs with regard to their ultimate goal of reducing breast
cancer mortality on the population level [20, 21]. Decreas-
ing breast cancer mortality due to advances in diagnostics
(such as the evolution from film to digital imaging systems
or improvements in evaluation skills for mammography
among radiologists) and treatment but also opportunistic
screening and low MSP participation makes it difficult to
analyze the isolated effect of a population-wide MSP on
breast cancer mortality [7, 19, 22].
Additional contributing factors such as attention or popu-
larity in media, the public discussion of such an extensive
health policy and consequences taken by individuals through
the awareness are too heterogeneous between the different
populations and are therefore analyzed as the aggregate effect
Table 1 MSPs in western European countries with more than 4.5 million inhabitants [7, 8, 10–15]
Country Implementation Perioda Age range of women eligible for screening Participation rate Years for analysis
Austriab 2014 50–69 – 2004–2017
Belgiumc 2001 50–69 2005: 38% [7] 1991–2015
Denmarkd 2007–2010 50–69 2010: 73% [12] 1997–2015
Finlande 1987 50–69 2010: 85% [12] 1980–2015
Francef 1989–2004 50–74 2010: 52% [12] 1980–2015
Germany 2005–2009 50–69 2014: 54% [14] 1995–2015
Italy 2002–2007 50–69 2010: 61% [12] 1992–2015
Netherlandsg 1988–1997 50–75 2010: 81% [12] 1980–2016
Norway 1996–2004 50–69 2010: 76% [12] 1986–2016
Portugalh 1990–1999 45–69 2010: 63/58% [12] 1989–2016
Spaini 1990–2003 50–69 2015: 75% [13] 1980–2016
Swedenj 1986–1996 40–74 2010: 70% [12] 1980–2016
Switzerlandk 1999–2004 50–70 2012: 46% [16] 1989–2015
United Kingdoml 1988–1995 50–70 2010: 73% [12] 1980–2015
aThe implementation period is defined as the year when the roll-out of a national MSP began until the year in which a 100% geographical national coverage was
achieved. The degree of completeness, measurable e.g. by % coverage by invitation, as well as pace and strategy of roll-out varies between countries
bIn Austria, an opportunistic screening without an invitation mechanism or dedicated mammography screening centers was introduced in 1974, but an organized
MSP was only introduced in 2014
cIn Belgium, the participation rate for 2005 is just for the province Flanders
dIn Denmark, a population-based screening program started in 1991 in Copenhagen and in 1993 in the region of Funen. In 2007, nationwide MSP was rolled out
eIn Finland, in some regions, the upper limit of invitation is 59, while in others 69
fIn France, partial regional screening was introduced in 1989, followed by a partial national screening covering some parts of France from 1994. The MSP was
initially planned for women aged 50–69 and the age-range was then extended to 50–74 [17]
gIn the Netherlands, an MSP for women aged 50–69 was implemented from 1987 to 1997 and extended to age 74 from 1998 to 2001 [18]
hIn Portugal, an MSP was launched in 1990 in the northern Central Region and in 1997 in the southern Alentejo Region. The participation rates are therefore
mentioned separately for these regions (63% in Central, 58% in Alentejo)
iIn Spain, the model of MSPs varies throughout the different states regarding screened age groups and initiation years. In most parts of the country, an organized
MSP was introduced during 1990–2003 targeting 50–69-year-old women. Some parts start screening already at age 45, other parts stop screening at 65
jIn Sweden, pilot projects started in 1982 and screening was recommended for women aged 50–69. Later the screened age range was extended
kIn Switzerland, the geographical coverage for organized MSPs in 2012 was 37%, and was still at 56% in 2015 [16]. The coverage by invitation within the target
population, however, was at 93% (2012) and 99% (2015) with participation rates of 46% (2012) and 41% (2015) respectively
lIn the United Kingdom, the screened age group was 50–64, from 1988 to 2001 [8]
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of implementation. Thus, we chose an ecological study ap-
proach to compare the developments of breast cancer
mortality across western European countries. Therefore,
our study focuses on the effect through the implementa-
tion of the MSP policy, rather than the isolated effect of
the measure itself.
Methods
First, we descriptively compared time trends in breast
cancer mortality rates across all 14 western European
countries with more than 4.5 million inhabitants in rela-
tion to the years of MSP implementation applying Join-
point regression. Second, we used interrupted time
series (ITS) to quantify the time trend change after MSP
implementation. Third, we utilized years of MSP imple-
mentation of each country to estimate an independent
effect through MSP implementation on breast cancer
mortality trends using Poisson regression.
Data
We extracted data on the number of female deaths from
breast cancer from the World Health Organization
(WHO) mortality database and respective mid-year
population figures from the WHO population database
for the 14 western European countries from 1980 on-
wards (Database from December 2018) [23]. The data
comprised population figures and deaths registered in
national vital registration systems, with underlying
causes of death as coded by the responsible national au-
thority. These data are official national statistics and
have been transferred to the WHO by the competent au-
thorities of the countries concerned. The International
Statistical Classification of Diseases and Related Health
Problems (ICD) codes for breast cancer were 174 (ICD-
8), 174 (ICD-9), and C50 (ICD-10).
Statistical analysis
We calculated yearly age-specific breast cancer mortality
rates for the following 10-year age groups: 50–59, 60–
69, 70–79 and analyzed yearly time trends for each
country separately using Joinpoint regression [24]. Join-
point regression identifies whether there are statistically
significant differences in time trends and allows to calcu-
late annual percentage changes (APC) for periods with
linear trends on a log scale [24]. In all Joinpoint analyses,
log transformation and a variance estimation based on the
Poisson distribution was used. In this descriptive part, the
time-period for analysis was set to 10 years prior and to
maximum 31 years post MSP implementation.
Joinpoint analyses were performed for each country
separately while ITS was performed on the aggregated
data from all 14 countries together for the time frame
from 1980 to 2017 and for the 3 ten-year age groups
separately. ITS is a common analysis to evaluate the
effectiveness of population-based interventions retro-
spectively [25]. We modeled the log of the observed
number of deaths using the log of the population figures
as the offset and “calendar year” (coded as “year–1980”)
and the interaction term between “calendar year” and a
binary variable indicating “availability of MSP” in the re-
spective year and country as given in Table 1.
Multivariable Poisson regression models were used to
further investigate the association between “calendar
year”, “year of MSP implementation”, “years with MSP”
and breast cancer mortality rates. The “year of MSP im-
plementation” was set to the year when MSP was first
publicly available (see Table 1) and thus coded as “year
of interest–1980”. “Years with MSP” is an additionally
constructed variable, which counts the years since MSP
implementation with values ranging from 0 to 31. For
each 10-year age group, we modeled the log of the ob-
served number of deaths using “calendar year”, “year of
MSP implementation” and “years with MSP” as inde-
pendent variables and the log of the population size as
the offset. Statistical analyses were performed using Join-
point Regression software (https://surveillance.cancer.
gov/joinpoint/) and Stata SE Version 15.
Results
Development of breast cancer mortality
Figure 1 shows trends of breast cancer-related mortality
rates (per 100,000) by country during 1980–2017 based
on data from 14 western European countries. To im-
prove comparability of results, the time frame of the
Joinpoint analysis was limited to 10 years before the
MSP implementations until the most recent year avail-
able in the WHO dataset from December 2018. The
most recent year available varies from 2015 to 2017 de-
pending on the country. Analysis were performed using
Joinpoint regression.
Trends of breast cancer-related mortality rates are
shown in Fig. 1. Overall, decreasing trends in breast can-
cer mortality can be observed throughout all analyzed
countries, ranging from − 1.5% to − 5.4% (50–59), − 0.2%
to − 8.1% (60–69) and 0% to − 7.1% (70–79) depending on
the country within 3 years after MSP implementation.
In the Netherlands, women aged 50–59 years already had
a declining trend of breast cancer mortality (APC: − 0.4%)
before the MSP initiation in the period 1980 to 1996. How-
ever, the reduction accelerated from 1996 onwards (APC:
− 2.6%). Among 60–69-year-old women, mortality rates
changed from a slight increasing trend (APC: 0.9%) be-
tween 1980 and 1990 to decreasing rates from 1990 on-
wards (APC: − 2%). In the 70–79-year-old group, an effect
of decreasing mortality rates was observed from 1997 on-
wards (APC < 1997: 0.3%; ≥1997: − 2.9%). In many other
countries such as Spain, Portugal or France, similar patterns
were observed.
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Fig. 1 Joinpoint analysis of breast cancer-related mortality rates since 1980 in 14 western European countries
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In Denmark, where a nationwide MSP was only imple-
mented in 2007, a regional MSP in densely populated areas
like Copenhagen and Funen had already existed since the
early 1990s [26]. The age group of 50–59–year-old women
showed a constant downward trend for the entire observa-
tion period (APC: − 4.5%). Whereas mortality among 60–
69-year-old women was slightly increasing before 2001
(APC: 1%), it decreased considerably thereafter (APC: −
3.9%). In the screening ineligible age group of 70–79-year-
old women, breast cancer mortality was somewhat decreas-
ing until 2007 (APC: − 0.4%) and then the trend further ac-
celerated with the introduction of the nationwide MSP
(APC: − 3.1%). In the United Kingdom, all three age groups
showed a significant change of their mortality trends close
to the MSP initiation in 1988 (APC 50–59 < 1988: 0.1%,
≥1988: -3.1%; APC 60–69 < 1990: 0.8%, ≥1990: -3.4%; APC
70–79 < 1988: 1.9%, ≥1988: − 1.8%).
In Finland an MSP was implemented in 1987, but in
some regions, it was only offered up to age 59 and in
other regions up to age 69. While for the age group of
50–59-year-old women there was a trend change in
1995 (APC < 1995: 0.7%, ≥1995: − 1.6%), the slightly de-
creasing trend remained constant for 60–69-year-old
women (APC − 0.2%). For women aged 70–79, mortality
remained constant over, showing no significant APC
change in the 39 years analyzed.
In Germany, an MSP was implemented in 2005. For
women aged 50–59 years, a constant decrease with an
APC of − 3.1% was observed since 1994. Among 60–69-
year-old women a stronger reduction was observed since
2008 (APC < 2008: − 0.1%, ≥2008: − 3%). For women aged
70–79 years, mortality slightly increased since 2008 (APC
< 2008: − 1.2%, ≥2008 0.7%). In contrast, in Norway the
screened age group of 50–59-year-old women showed an
acceleration in the decreasing trend 4 years after the im-
plementation of an MSP (APC < 2000: − 0.7%, ≥2000–
3.5%), while the other age groups had a declining trend
with no APC changes in close proximity to the implemen-
tation of an MSP.
In Italy and Sweden, a nationwide MSP implementation
took a long time and varied strongly depending on the re-
gion of these countries. We observed a general decreasing
trend in breast cancer mortality in these countries across
all age groups, irrespective of the MSP implementation. For
Belgium and Switzerland, we also observed general declin-
ing breast cancer mortality trends over time, without an ac-
celerated reduction after MSP implementation. In Austria,
an MSP was implemented in 2014; thus, it is too early to
see possible changes in its decreasing trends in breast can-
cer mortality due to the implementation of its MSP.
Interrupted time series regression
The results of the ITS analyses are shown in Table 2 and
are based on the combined data from all 14 countries.
All three age-specific models resulted in decreasing calendar
year effects with yearly rate ratios (RR) of 0.987, 0.992 and
0.998 for the age groups 50–59, 60–69, 70–79, respectively.
For the oldest age group, the effect was not significant. Fur-
ther, all models estimated highly significant interaction
terms indicating an additional decrease in breast cancer
mortality with yearly RR ranging from 0.996 to 0.997.
Multivariable Poisson regression
Results of the multivariable Poisson regression analysis
are presented in Table 3 and are based on the combined
data from all 14 countries. The independent effects of
variables “calendar year”, “year of MSP implementation”
and “years with MSP” on breast cancer mortality were
also estimated in three age-specific models. In each
model, the estimates that were highly significant with
p < 0.001 are shown in bold. For the “calendar year” ef-
fect, the estimated yearly RR for the age group of 50–59
was 0.987 [95% confidence interval (CI), 0.984; 0.990],
0.996 [95% CI, 0.992; 0.999] for 60–69 and 0.992 [95%
CI, 0.995; 0.999] for 70–79. The “year of MSP imple-
mentation” was estimated with an RR of 0.995 [95% CI,
0.992; 0.998] for the youngest group, 0.996 [95% CI,
0.992; 0.999] for the 60–69 age group and 0.998 [95%
CI, 0.994; 0.999] for the oldest age group. “years with
MSP” is in the focus of interest and results in RR esti-
mates of 0.991 [95% CI, 0.987; 0.996], 0.988 [95% CI,
0.987; 0.993] and 0.991 [95% CI, 0.986; 0.996] for the re-
spective age groups.
Discussion
Overall, the development of breast cancer mortality trends
across 14 western European countries supports previous
studies on the effectiveness of the implementation of
MSPs on the reduction of breast cancer mortality. Results
from descriptive as well as regression analyses support an
overall positive effect of MSP implementation on declin-
ing breast cancer mortality by suggesting an accelerated
decline after MSP implementation.
However, due to the complexity of the topic and the
nature of this study, the outcome has to be interpreted
with caution and the following limitations have to be
considered. The time frame of the Joinpoint analysis was
limited to 10 years before the MSP implementations for
each country, to improve comparability of the results as
demonstrated in Fig. 1. The exclusion of data may lead
to the exclusion of certain trend changes. However, in a
sensitivity analysis (results not shown) including the
complete data from 1980 onwards for all countries, the
results remained mainly unchanged.
The age group of 70–79 old women does not partici-
pate directly in the MSP, but following the implementa-
tion of an MSP, every year, more women in this group
were eligible for the mammography earlier in their life.
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Therefore, an even more delayed effect might be ex-
pected in this age group as observed in countries such
as Denmark or the Netherlands. Overall, Joinpoint re-
gression results are in line with findings from previous
studies examining time trends in breast cancer mortality
[27, 28]. Previous studies from Italy, Sweden and
Norway reported a positive association between MSP
implementation and breast cancer mortality [29–31].
These studies used mortality data on a regional level and
were able to define “year of MSP implementation” more
accurately than we did, which is particularly important
for countries like Italy, Sweden and Norway, since the
MSP implementation period was rather long in these
countries and regional heterogeneity regarding the MSP
implementation was observed. Therefore, the country-
specific association between MSP implementation and
breast cancer mortality might be somewhat blurred in
our results for these countries.
Regarding the regression analyses, we want to clearly
state that we did not consider a time lag between MSP
implementation and mortality reduction. However, we
consider this a minor problem and we think any consid-
eration of a time lag would be artificial since this study
looked at the population-wide effect of MSP implemen-
tation which includes effects due to the healthcare policy
e.g. raised awareness in the population even before the
implementation. Furthermore, the Joinpoint analysis
suggested that an effect may already be seen in most of
the countries shortly after MSP initiation. Similar breast
cancer mortality trend changes soon after MSP imple-
mentation were already observed in several studies in
the Netherlands [18, 32]. The authors argue that the
expectation for the effect of screening revealing to its
fullest after 3 to 5 years is based on randomized con-
trolled trials from the 1980s with rather small study pop-
ulations. The effect on large country-wide populations
with many more cases might be underestimated due to
the increased survival of women with metastasized
breast cancer who, without screening, would not have
been diagnosed and treated. They state the decline to be
a combined effect of the increased use of adjuvant ther-
apy and the implementation of an MSP and that it is
common to see a first change in trend before the full ef-
fect of screening can be observed.
With regard to the multivariable regression, it is essential
to discuss each of the incorporated variables thoroughly
and be aware of their limitations. The “calendar year” effect
should mainly reflect components such as the improve-
ment of medical treatment and greater breast cancer aware-
ness over time. In the 1980s, tamoxifen and chemotherapy
were introduced, followed by the sentinel-lymph-node-bi-
opsy in the 1990s. In the beginning of the 2000s, the posi-
tive association between hormone replacement therapy and
breast cancer incidence and mortality increase was revealed
in several studies and led to a far more cautious use of
these ever since [33]. Another considerable advance in
breast cancer treatment was the introduction of monoclo-
nal antibody therapy in the mid-2000s against HER2+
breast cancer, which is a highly lethal type of breast cancer
and contributes to 20–30% of all breast cancers [34]. Today,
the therapy with antibodies like trastuzumab is standard of
care for these cancers, and its introduction had an indisput-
able positive effect on the overall survival of patients with a
prolongation of survival of more than 4.5 years [34]. The
Table 2 Interrupted time series regression based on combined data from all 14 western European countries
Age 50–59 Age 60–69 Age 70–79
Estimate p-value Estimate p-value Estimate p-value
Constant −7.266 < 0.001 −6.988 < 0.001 −6.737 < 0.001
Calendar year (year-1980) −0.013 < 0.001 − 0.008 0.004 − 0.002 0.190
Interaction term (Availability of MSP × Calendar year) − 0.004 < 0.001 − 0.003 < 0.001 −0.004 < 0.001
Results of the interrupted time series regression on the association between independent variables calendar year and an interaction term for calendar year and
the availability of MSP and breast cancer mortality. The analysis was performed based on combined data from all 14 western European countries considered in
this study. Results are presented for the three defined age groups (50–59, 60–69, 70–79) separately.
Table 3 Multivariable Poisson regression with independent variables: “calendar year”, “year of MSP implementation”, “years with MSP”
Age 50–59 Age 60–69 Age 70–79
Estimate 95% CI Estimate 95% CI Estimate 95% CI
Constant −7.196 −7.240 − − 7.152 −6.950 − 6.997 − − 6.904 −6.703 − 6.715 − − 6.654
Calendar year (year-1980) −0.013 − 0.016 − − 0.010 −0.004 − 0.008 − − 0.001 −0.002 − 0.005 – 0.001
Year of MSP implementation
(year-1980)
−0.005 − 0.008 − − 0.002 −0.004 − 0.008 − − 0.001 −0.002 − 0.006 − 0.001
Years with MSP (0–31) − 0.009 −0.013 − − 0.004 −0.012 − 0.017 − − 0.007 −0.009 − 0.014 − − 0.004
Results of multivariable Poisson regression of the association between “calendar year”, “year of MSP implementation” and “years with MSP” and breast cancer
mortality in three different age groups (50–59, 60–69, 70–79). The analysis was performed based on combined data from all 14 western European countries
considered in this study. Effect estimates with p-values< 0.001 are indicated in bold.
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continuous improvements, especially in the sector of
chemotherapy, also contributed to regular recurrence rate
and subsequent mortality rate reduction [35]. Any innova-
tive therapy is introduced successively into healthcare sys-
tems, usually starting with a small group of patients in
urban areas around university hospitals followed by a slow
spill over to the rest of the population. Therefore, it is diffi-
cult to isolate and consider the mentioned effects in the
analysis without detailed country-specific data, which is not
available for this large time frame and populations. Yet, a
recent study has shown that patients participating in MSPs
benefit even more from advanced therapeutic options avail-
able and advances in treatment options should therefore
not be seen as an argument against but rather as a further
benefit for the effectiveness of MSPs [36].
“Year of MSP implementation” tries to address continu-
ous advances in technological diagnostics and improve-
ments of MSP programs through quality management
measures available at the initiating point in time. However,
exact years of implementation are not available since im-
plementation usually took several years. Regarding oppor-
tunistic screening, it is very challenging to quantify the
scale and impact of it on a population level, and there
have only been few studies comparing organized programs
to opportunistic breast cancer screenings. Some demon-
strated the advantages of higher sensitivities and specific-
ities of MSPs while others stated no difference in
effectiveness [19, 37]. In most of the countries, opportun-
istic screening is not being reimbursed by public health in-
surances. The implementation of MSPs and the presence
of the topic through awareness campaigns in media and
society could have led to an increase in opportunistic
screening activity, which in the end contributed to the de-
crease in mortality [38].
“Years with MSP” aims to assess the independent time
effect on mortality since MSP implementation.
We were not able to account for a possible non-linear
association between MSP implementation and breast can-
cer mortality in our regression models. Modeling based
on country-level aggregated data reduces the absolute
sample size considerably and does not allow to adequately
model more complex functional forms in order to provide
estimates of satisfying precision. Furthermore, we want to
explicitly state, that the time variables are partially corre-
lated, which may yield biased estimates.
In summary, we acknowledge the limitations of the re-
gression analyses and especially the magnitude of the mod-
eled effects should be interpreted with caution, but results
support and supplement the descriptive Joinpoint analysis.
Finally, this study does not consider in its analysis nor
can give quantitative answers to some of the remaining
controversial aspects discussed between supporters and
critics of MSPs, including the ones that do not directly
affect mortality-based effectiveness measurement of
MSPs. These aspects include cost-benefit ratios, radiation-
induced cancer, balance between mortality reduction vs.
over-diagnosis, optimum screening age range, alternative
imaging or even screening techniques and many more.
Furthermore, we did not use incidence-based mortality
rates even though this may have shown a stronger decline
since in the early years, most deaths have already been di-
agnosed before MSP implementation. However, this data
is not directly available for all countries. Additionally, our
study did not assess the isolated effect of the MSP itself,
but rather the aggregated effect of MSP implementations,
which also has an effect on women who were not yet in-
vited to the MSP. MSPs are still the only scientifically
proven method for an effective population-wide early de-
tection of breast cancer in the age range from 50 to 69 so
far. Alternative imaging techniques such as sonography or
MRI can certainly be helpful adjunctive screening tools
for specific patient groups [39]. Novel epigenetic-based
screening approaches are constantly being discussed as
potential successors of MSPs, but are still only in trial
stages and have yet to be proven to be reliable and feasible
on a population-wide scale and especially in the age range
of patients targeted by MSPs [40].
Other studies such as an evaluation of various po-
tential influencing factors on breast cancer mortality
reduction including MSPs in Switzerland using Bayes-
ian hierarchical spatiotemporal models did not show
a direct link between screening and breast cancer
mortality reduction [41]. In contrast, the International
Agency for Research on Cancer has published an ex-
tensive review in 2016 focusing on all the controver-
sial aspects mentioned above. These experts from
more than 16 countries concluded and reaffirmed that
women attending the MSP according to the EUREF
guidelines would benefit with a mortality reduction of
around 40% [42, 43].
Conclusions
Driven by the controversial discussion on MSP effectiveness
and risk-benefit ratios across countries, we analyzed the
overall trend across 14 western European countries over a
time frame of 38 years. Our multinational ecologic study ap-
proach showed that the policy of implementing MSPs had a
noticeable impact contributing to the reduction of breast
cancer mortality, and further supports past studies demon-
strating the effectiveness of MSPs [27, 36, 44]. However, the
specific extent to which MSPs themselves contribute to re-
ducing breast cancer mortality remains challenging to be
quantified and should be an objective of further research
with detailed individual data.
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